
Repairing MS-caused damage with stem cells
Results of a investigator-initiated Phase I stem cell therapy trial have shown promise as a treatment for progressive multiple sclerosis. The...

Oxford Biomedica acquires ABL Europe for €15m
Oxford Biomedica PLC, and Institut Mérieux have entered exclusive negotiations for the acquisition of ABL Europe Inc. This move is set to solidify...

Radiotherapy R&D partnership
French-US company Orano Med is developing Lead-212 (212Pb) Targeted Alpha Therapy, which combines the ability of biological molecules such as...

Sanofi licences vaccine against bacterial sepsis
Extraintestinal pathogenic E. coli (ExPEC) is a leading bacterial cause of sepsis, causing approximately 10 million cases of invasive E. coli...

VectorY Therapeutics raises €129m in Series A round
EQT Life Sciences and Forbion co-led the €129m Series A financing that will support clinical development of VectorY Therapeutics BVs lead...

CPHI: Trends shaping pharma's path
Despite challenges such as funding slowdowns for biotechs and concerns about high inflation, the industry remains cautiously optimistic,...

AI protein specialist Cradle raises US$24m in Series A financing
Kindred Capital. and angel investors including Recursion CEO Chris Gibson and Tom Glocer, Lead Director, Merck participated it the US24m Series A...